Venetoclax
Product Type
Impurity Standards
CAT. No.
MRL-V07001
CAS. No.
1257044-40-8
Mol. F.
C45H50ClN7O7S
Mol. Wt.
868.45
Synonyms
NA
Chemical Name
4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
Stock Status
Custom Synthesis
Venetoclax is a BCL-2 inhibitor prescribed for the treatment of certain blood cancers, notably chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Operating by inhibiting the B-cell lymphoma-2 (BCL-2) protein, Venetoclax disrupts the survival mechanisms of cancer cells, triggering programmed cell death. It is often utilized in combination with other anti-cancer drugs, particularly in cases where the cancer cells exhibit the 17p deletion genetic abnormality, making them less responsive to standard treatments. The use of Venetoclax is carefully managed by healthcare professionals to ensure its efficacy and monitor potential side effects throughout the treatment course. Buy high quality Venetoclax from Molsyns Research. Molsyns Research is one of the leading manufacturer and exporter of Venetoclax
